Financials data is unavailable for this security.
View more
Year on year PTC Therapeutics Inc had net income fall 12.09% from a loss of 559.02m to a larger loss of 626.60m despite a 34.20% increase in revenues from 698.80m to 937.82m.
Gross margin | 92.35% |
---|---|
Net profit margin | -53.25% |
Operating margin | -37.27% |
Return on assets | -29.47% |
---|---|
Return on equity | -- |
Return on investment | -44.23% |
More ▼
Cash flow in USDView more
In 2023, PTC Therapeutics Inc increased its cash reserves by 106.23%, or 314.36m. Cash Flow from Financing totalled 646.40m or 68.93% of revenues. In addition the company used 158.42m for operations while cash used for investing totalled 176.74m.
Cash flow per share | -3.61 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -12.75 |
---|---|
Tangible book value per share | -18.11 |
More ▼
Balance sheet in USDView more
Current ratio | 2.23 |
---|---|
Quick ratio | 2.17 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 1.70 |
More ▼